BioSpace News Archive

ImmunAbs, a leading clinical-stage biotechnology company focused on developing novel antibody therapeutics, announced the successful completion of the Phase 1 clinical trial for IM-101.

QIAGEN N.V. announced that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended December 31, 2023, with the U.S. Securities and Exchange Commission.

Fortrea, a leading global contract research organization, announced it has signed a definitive agreement to divest assets relating to its Enabling Services segment, namely its Endpoint Clinical and Fortrea Patient Access businesses, to Arsenal Capital Partners, a leading private equity firm specializing in building market-leading, technology-rich healthcare companies.

Mallinckrodt plc announced the publication of findings from a retrospective chart review of Acthar® Gel treatment outcomes for African American and non-African American patients with symptomatic sarcoidosis – including treatment patterns, co-medication use, and overall health outcomes.

Microbix Biosystems Inc., a life sciences innovator, manufacturer, and exporter, announces that it is presenting results of Quality Assessment Products for supporting the quality control of histology and PCR-based tests driven by tissue-samples of Head and Neck cancer caused by human papilloma virus.

Conduit Pharmaceuticals Inc. announced the opening of cutting-edge laboratory space in Cambridge, United Kingdom, a global centre for research and development for companies at the forefront of life science innovation.

FibroGen, Inc. announced the appointment of Deyaa Adib, M.D., an executive leader with almost three decades of oncology development experience, as Senior Vice President & Chief Medical Officer to oversee all global clinical development activities.

ONWARD Medical N.V. announces that it has been accepted into the US FDA’s new Total Product Lifecycle Advisory Program for its brain-computer interface technology.

Boehringer Ingelheim and Sosei Group Corporation announced they have entered a global collaboration and exclusive option-to-license agreement.

Ubiquigent Limited, a drug discovery and development company harnessing novel deubiquitinase modulators as new therapeutics for areas of high unmet medical need, announced an agreement with Nanna Therapeutics.